On this week's CBS Sunday Morning with host Jane Pauley the FDA's recent approval of a new drug Aduhelm to clear the formation of amyloid plaques in the brain is potentially good news for the six million Americans who suffer from Alzheimer's disease But the approval process for Aduhelm has stirred controversy Correspondent Susan Spencer talks with experts about the clinical benefits of this new class of drugs and with early-onset Alzheimer's patients including a former neurologist who enrolled in an early trial of Aduhelm As the effects of the COVID- pandemic begin to wane prices are up because supply
[... more]